spironolactone has been researched along with dihydropyridines in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, T; Miyabo, S; Nakai, T | 1 |
| Burnier, M; Pechère, A; Waeber, B | 1 |
| Bärfacker, L; Heidland, A; Kolkhof, P; Queisser, N; Schäfer, S; Schupp, N; Stopper, H; Wolf, M | 1 |
| Hirayama, K; Kitayama, T; Kosaka, H; Kusaka, H; Matsubara, M; Sasaki, K; Yoda, N | 1 |
| Arhancet, GB; Blinn, JR; Collins, JT; Dietz, JD; Garland, DJ; Hu, X; Huang, HC; Iyanar, K; Numann, RE; Wagner, GM; Woodard, SS | 1 |
| Inagaki, K; Kumagai, I; Makino, H; Miyoshi, T; Nakamura, E; Ogura, T; Otsuka, F; Suzuki, J; Tanabe, K; Tsukamoto, N | 1 |
| Deinum, J; Lenders, JW; Riksen, NP | 1 |
1 review(s) available for spironolactone and dihydropyridines
| Article | Year |
|---|---|
Pharmacological treatment of aldosterone excess.
Topics: Aldosterone; Cytochrome P-450 CYP11B2; Dihydropyridines; Drug Interactions; Epithelial Sodium Channel Blockers; Eplerenone; Glucocorticoids; Heart Failure; Hyperaldosteronism; Hypertension; Mineralocorticoid Receptor Antagonists; Spironolactone | 2015 |
6 other study(ies) available for spironolactone and dihydropyridines
| Article | Year |
|---|---|
Glucocorticoids increase Ca2+ uptake and [3H]dihydropyridine binding in A7r5 vascular smooth muscle cells.
Topics: Amiloride; Analysis of Variance; Androstanols; Animals; Calcium; Calcium Channels; Cell Count; Cell Line; Cycloheximide; Dactinomycin; Dexamethasone; Dihydropyridines; Electric Conductivity; Glucocorticoids; Indomethacin; Kinetics; Muscle, Smooth, Vascular; Potassium; Proteins; Rats; Receptors, Glucocorticoid; Spironolactone; Water | 1991 |
[Antihypertensive agents used as first line agents: beta-blockers under pressure].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Dihydropyridines; Diuretics; Drug Therapy, Combination; Eplerenone; Humans; Hypertension; Spironolactone; Treatment Outcome | 2006 |
Aldosterone causes DNA strand breaks and chromosomal damage in renal cells, which are prevented by mineralocorticoid receptor antagonists.
Topics: Aldosterone; Animals; Cells, Cultured; Chromones; Chromosomes; Comet Assay; Cytoprotection; Dihydropyridines; DNA Breaks; DNA Damage; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Hormone Antagonists; Kidney; Micronucleus Tests; Mifepristone; Mineralocorticoid Receptor Antagonists; Spironolactone; Swine | 2010 |
The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family.
Topics: Aldosterone; Binding Sites; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Calcium Channels, T-Type; Cell Line; Dihydropyridines; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; Models, Molecular; Molecular Conformation; Mutation; Pyridines; Receptors, Mineralocorticoid; Spironolactone; Stereoisomerism | 2010 |
Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Crystallography, X-Ray; Dihydropyridines; Eplerenone; Genes, Reporter; Humans; Luciferases; Mineralocorticoid Receptor Antagonists; Models, Molecular; Protein Binding; Rats; Receptors, Mineralocorticoid; Spironolactone; Stereoisomerism; Structure-Activity Relationship | 2010 |
Effects of eplerenone on nephrotic syndrome in a patient with renovascular hypertension.
Topics: Amlodipine; Antihypertensive Agents; Dihydropyridines; Eplerenone; Humans; Hypertension, Renovascular; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Nephrotic Syndrome; Proteinuria; Radiography; Spironolactone; Treatment Outcome | 2011 |